{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Julg B"],"funding":["Ragon Institute of MGH, MIT and Harvard (Ragon Institute)","U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)","Ragon Institute of MGH, MIT and Harvard"],"pagination":["89"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11116546"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Mosaic HIV-1 vaccines have been shown to elicit robust humoral and cellular immune responses in people living with HIV-1 (PLWH), that had started antiretroviral therapy (ART) during acute infection. We evaluated the safety and immunogenicity of 2 mosaic vaccine regimens in virologically suppressed individuals that had initiated ART during the chronic phase of infection, exemplifying the majority of PLWH. In this double-blind, placebo-controlled phase 1 trial (IPCAVD013/HTX1002) 25 ART-suppressed PLWH were randomized to receive Ad26.Mos4.HIV/MVA-Mosaic (Ad26/MVA) (n = 10) or Ad26.Mos4.HIV/Ad26.Mos4.HIV plus adjuvanted gp140 protein (Ad26/Ad26+gp140) (n = 9) or placebo (n = 6). Primary endpoints included safety and tolerability and secondary endpoints included HIV-specific binding and neutra"],"journal":["NPJ vaccines"],"pubmed_title":["Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy."],"pmcid":["PMC11116546"],"funding_grant_id":["R01 AI149670","P01 AI177687","AI149670","AI169615","AI164556","AI128751","U19 AI128751","UM1 AI164556","R01 AI138790","Internal grant","AI138790","P01 AI169615","AI177687"],"pubmed_authors":["Pattacini L","Walker BD","Ansel JL","Ilan S","Schuitemaker H","Tomaka F","Jaegle K","Seaman MS","Speidel T","Kanjilal DG","Walsh SR","van Duijn J","Stieh DJ","Willems W","Burgess E","Julg B","Sabrina Tan C","Bartsch Y","Borducchi EN","Pau MG","Barouch DH","Lavreys L","Yanosick KE","Robb ML","Nkolola JP","Sarnecki M","Michael NL","Stephenson KE","Braams E"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy.","description":"Mosaic HIV-1 vaccines have been shown to elicit robust humoral and cellular immune responses in people living with HIV-1 (PLWH), that had started antiretroviral therapy (ART) during acute infection. We evaluated the safety and immunogenicity of 2 mosaic vaccine regimens in virologically suppressed individuals that had initiated ART during the chronic phase of infection, exemplifying the majority of PLWH. In this double-blind, placebo-controlled phase 1 trial (IPCAVD013/HTX1002) 25 ART-suppressed PLWH were randomized to receive Ad26.Mos4.HIV/MVA-Mosaic (Ad26/MVA) (n = 10) or Ad26.Mos4.HIV/Ad26.Mos4.HIV plus adjuvanted gp140 protein (Ad26/Ad26+gp140) (n = 9) or placebo (n = 6). Primary endpoints included safety and tolerability and secondary endpoints included HIV-specific binding and neutra","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-07-15T09:24:46.994Z","creation":"2026-07-02T03:11:20.484Z"},"accession":"S-EPMC11116546","cross_references":{"pubmed":["38782902"],"doi":["10.1038/s41541-024-00876-2"]}}